R01MH127686
Project Grant
Overview
Grant Description
Assessing the Effectiveness of a Digital Platform to Support the Mental Health of Healthcare Workers in the Response and Recovery Phases of COVID-19
The novel coronavirus (COVID-19) has radically changed the delivery of healthcare and significantly impacted the mental health of individuals and communities. The effect on the mental health of the healthcare workforce has been particularly strained throughout the various phases of the pandemic. This impact is predicted to be chronic and pervasive for all, and particularly for disproportionately affected underrepresented minority and female populations.
There is a critical need to develop and test scalable digital approaches which can identify, address, and support the well-being of healthcare workers (HCW) over time and beyond the pandemic. HCWs are busy, and there is stigma associated with accessing mental health support. We seek to leverage digital platforms to facilitate ease of access to well-being focused resources and direct connection to mental health providers through real-time support using a stepped model of care.
During the acute phase of the pandemic, our team developed and implemented Penn COBALT across the Penn Medicine health system. COBALT is a web and text-message based platform which allows HCWs to complete contextual surveys and evidence-based assessments remotely on their own time. Individuals are then directed to tailored well-being resources and appropriate individual or group mental healthcare.
Across Penn Medicine, and in just 7 months, COBALT has had 18,300 unique users and has identified 111 HCWs reporting thoughts of self-harm, immediately connecting those individuals with a mental health provider for support and evaluation. While COBALT has had sustained high engagement and increased the health system's ability to identify high-risk individuals, it requires a motivated user. Individuals must "pull" care toward them and overcome multiple barriers ranging from identifying the need for mental health support to making an appointment and attending the appointment.
We seek to evaluate whether a "pushed" model of care (COBALT+), which proactively engages individuals, can improve individual mental health, satisfaction with access, and decrease factors which affect workforce productivity (e.g. absenteeism). The specific aims will evaluate, through a randomized controlled trial, the effectiveness of COBALT+ on HCW depression/anxiety (primary outcome) compared with COBALT (usual care). Secondary outcomes will include well-being, satisfaction with access to care, and measures of work productivity. Heterogeneous treatment effects will be explored for race and gender.
Additionally, we will seek to better understand perceptions of access to mental health care and the effectiveness of COBALT compared with COBALT among HCWs through semi-structured qualitative interviews. Overall, this project seeks to address a significant gap and enhance HCW access and receipt of mental health and well-being focused resources and care. Our intent is that this will enable a proactive culture of well-being and mental health support for the healthcare workforce during the multiple phases of the pandemic.
Our approach evaluates existing digital models which can be executed in a timely fashion and rapidly scaled for use across other health systems.
The novel coronavirus (COVID-19) has radically changed the delivery of healthcare and significantly impacted the mental health of individuals and communities. The effect on the mental health of the healthcare workforce has been particularly strained throughout the various phases of the pandemic. This impact is predicted to be chronic and pervasive for all, and particularly for disproportionately affected underrepresented minority and female populations.
There is a critical need to develop and test scalable digital approaches which can identify, address, and support the well-being of healthcare workers (HCW) over time and beyond the pandemic. HCWs are busy, and there is stigma associated with accessing mental health support. We seek to leverage digital platforms to facilitate ease of access to well-being focused resources and direct connection to mental health providers through real-time support using a stepped model of care.
During the acute phase of the pandemic, our team developed and implemented Penn COBALT across the Penn Medicine health system. COBALT is a web and text-message based platform which allows HCWs to complete contextual surveys and evidence-based assessments remotely on their own time. Individuals are then directed to tailored well-being resources and appropriate individual or group mental healthcare.
Across Penn Medicine, and in just 7 months, COBALT has had 18,300 unique users and has identified 111 HCWs reporting thoughts of self-harm, immediately connecting those individuals with a mental health provider for support and evaluation. While COBALT has had sustained high engagement and increased the health system's ability to identify high-risk individuals, it requires a motivated user. Individuals must "pull" care toward them and overcome multiple barriers ranging from identifying the need for mental health support to making an appointment and attending the appointment.
We seek to evaluate whether a "pushed" model of care (COBALT+), which proactively engages individuals, can improve individual mental health, satisfaction with access, and decrease factors which affect workforce productivity (e.g. absenteeism). The specific aims will evaluate, through a randomized controlled trial, the effectiveness of COBALT+ on HCW depression/anxiety (primary outcome) compared with COBALT (usual care). Secondary outcomes will include well-being, satisfaction with access to care, and measures of work productivity. Heterogeneous treatment effects will be explored for race and gender.
Additionally, we will seek to better understand perceptions of access to mental health care and the effectiveness of COBALT compared with COBALT among HCWs through semi-structured qualitative interviews. Overall, this project seeks to address a significant gap and enhance HCW access and receipt of mental health and well-being focused resources and care. Our intent is that this will enable a proactive culture of well-being and mental health support for the healthcare workforce during the multiple phases of the pandemic.
Our approach evaluates existing digital models which can be executed in a timely fashion and rapidly scaled for use across other health systems.
Funding Goals
THE MISSION OF THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) IS TO TRANSFORM THE UNDERSTANDING AND TREATMENT OF MENTAL ILLNESSES THROUGH BASIC AND CLINICAL RESEARCH, PAVING THE WAY FOR PREVENTION, RECOVERY, AND CURE. IN MAY 2020, NIMH RELEASED ITS NEW STRATEGIC PLAN FOR RESEARCH. THE NEW STRATEGIC PLAN BUILDS ON THE SUCCESSES OF PREVIOUS NIMH STRATEGIC PLANS BY PROVIDING A FRAMEWORK FOR SCIENTIFIC RESEARCH AND EXPLORATION, AND ADDRESSING NEW CHALLENGES IN MENTAL HEALTH. THE NEW STRATEGIC PLAN OUTLINES FOUR HIGH-LEVEL GOALS: GOAL 1: DEFINE THE BRAIN MECHANISMS UNDERLYING COMPLEX BEHAVIORS GOAL 2: EXAMINE MENTAL ILLNESS TRAJECTORIES ACROSS THE LIFESPAN GOAL 3: STRIVE FOR PREVENTION AND CURES GOAL 4: STRENGTHEN THE PUBLIC HEALTH IMPACT OF NIMH-SUPPORTED RESEARCH THESE FOUR GOALS FORM A BROAD ROADMAP FOR THE INSTITUTE'S RESEARCH PRIORITIES OVER THE NEXT FIVE YEARS, BEGINNING WITH THE FUNDAMENTAL SCIENCE OF THE BRAIN AND BEHAVIOR, AND EXTENDING THROUGH EVIDENCE-BASED SERVICES THAT IMPROVE PUBLIC HEALTH OUTCOMES. THE INSTITUTE'S OVERALL FUNDING STRATEGY IS TO SUPPORT A BROAD SPECTRUM OF INVESTIGATOR-INITIATED RESEARCH IN FUNDAMENTAL SCIENCE, WITH INCREASING USE OF INSTITUTE-SOLICITED INITIATIVES FOR APPLIED RESEARCH WHERE PUBLIC HEALTH IMPACT IS A SHORT-TERM MEASURE OF SUCCESS. THE NEW STRATEGIC PLAN ALSO ADDRESSES A NUMBER OF CROSS-CUTTING THEMES THAT ARE RELEVANT TO ALL RESEARCH SUPPORTED BY NIMH, THESE THEMES HIGHLIGHT AREAS WHERE NIMH-FUNDED SCIENCE MAY HAVE THE GREATEST IMPACT, BRIDGE GAPS, AND OFFER NOVEL APPROACHES TO ACCELERATE ADVANCES IN MENTAL HEALTH RESEARCH. FOR EXAMPLE, NIMH VALUES A COMPREHENSIVE RESEARCH AGENDA THAT TAKES AN INCLUSIVE APPROACH THAT ENSURES RESEARCH INTERESTS ARE VARIED, MAINTAIN DIVERSE PARTICIPATION AND PARTNERSHIPS, AND ACHIEVE RESEARCH GOALS ACROSS MULTIPLE TIMEFRAMES. THIS INCLUDES DIVERSE METHODOLOGIES, TOOLS, AND MODELS, RESEARCH ADDRESSING COMPLEX BASIC, TRANSLATIONAL, AND APPLIED QUESTIONS, RESEARCH INCLUDING BOTH SEXES AND, AS APPROPRIATE, GENETIC BACKGROUND, AND, PARTICIPANTS FROM DIVERSE RACIAL AND ETHNIC BACKGROUNDS, AND ACROSS GENDER IDENTITIES, GEOGRAPHICAL CONTEXT, SOCIOECONOMIC STATUS, NEUROTYPE, AND AGE OFFERING THE BEST POSSIBLE REPRESENTATION, FOR THE BROADEST NUMBER OF INDIVIDUALS WHO MAY ULTIMATELY BENEFIT FROM THESE SCIENTIFIC ADVANCES. TO ACCOMPLISH THE GOALS OUTLINED IN THE NEW STRATEGIC PLAN, NIMH WILL SUPPORT RESEARCH THAT AIMS: TO CHARACTERIZE THE GENOMIC, MOLECULAR, CELLULAR, AND CIRCUIT COMPONENTS CONTRIBUTING TO BRAIN ORGANIZATION AND FUNCTION, TO IDENTIFY THE DEVELOPMENTAL, FUNCTIONAL, AND REGULATORY MECHANISMS RELEVANT TO COGNITIVE, AFFECTIVE, AND SOCIAL DOMAINS, ACROSS UNITS OF ANALYSIS, AND, TO GENERATE AND VALIDATE NOVEL TOOLS, TECHNIQUES, AND MEASURES TO QUANTIFY CHANGES IN THE ACTIVITY OF MOLECULES, CELLS, CIRCUITS, AND CONNECTOMES. TO DISCOVER GENE VARIANTS AND OTHER GENOMIC ELEMENTS THAT CONTRIBUTE TO THE DEVELOPMENT OF MENTAL ILLNESSES IN DIVERSE POPULATIONS, TO ADVANCE OUR UNDERSTANDING OF THE COMPLEX ETIOLOGY OF MENTAL ILLNESSES USING MOLECULAR EPIDEMIOLOGIC APPROACHES THAT INCORPORATE INDIVIDUAL GENETIC INFORMATION IN LARGE COHORTS, TO ELUCIDATE HOW HUMAN GENETIC VARIATION AFFECTS THE COORDINATION OF MOLECULAR, CELLULAR, AND PHYSIOLOGICAL NETWORKS SUPPORTING HIGHER-ORDER FUNCTIONS AND EMERGENT PROPERTIES OF NEUROBIOLOGICAL SYSTEMS, AND, TO DEVELOP NOVEL TOOLS AND TECHNIQUES FOR THE ANALYSIS OF LARGE-SCALE GENETIC, MULTI-OMIC DATA AS IT APPLIES TO MENTAL HEALTH. TO UTILIZE CONNECTOMIC APPROACHES TO IDENTIFY BRAIN NETWORKS AND CIRCUIT COMPONENTS THAT CONTRIBUTE TO VARIOUS ASPECTS OF MENTAL FUNCTION AND DYSFUNCTION, TO DETERMINE THROUGH BRAIN-WIDE ANALYSIS HOW CHANGES IN THE PHYSIOLOGICAL PROPERTIES OF MOLECULES, CELLS, AND CIRCUITS CONTRIBUTE TO MENTAL ILLNESSES, TO DEVELOP MOLECULAR, CELLULAR, AND CIRCUIT-LEVEL BIOMARKERS OF IMPAIRED NEURAL FUNCTION IN HUMANS, AND, TO DEVELOP INNOVATIVE TECHNOLOGIES, INCLUDING NEW IMAGING, COMPUTATIONAL, PHARMACOLOGICAL, AND GENETIC TOOLS TO INTERROGATE AND MODULATE CIRCUIT ACTIVITY AND STRUCTURE ALTERED IN MENTAL ILLNESSES. TO ELUCIDATE THE MECHANISMS CONTRIBUTING TO THE TRAJECTORIES OF BRAIN DEVELOPMENT AND BEHAVIOR, AND, TO CHARACTERIZE THE EMERGENCE AND PROGRESSION OF MENTAL ILLNESSES, AND IDENTIFYING SENSITIVE PERIODS FOR OPTIMAL INTERVENTION. TO DETERMINE EARLY RISK AND PROTECTIVE FACTORS, AND RELATED MECHANISMS, TO SERVE AS NOVEL INTERVENTION GROUPS, AND, TO DEVELOP RELIABLE AND ROBUST BIOMARKERS AND ASSESSMENT TOOLS TO PREDICT ILLNESS ONSET, COURSE, AND ACROSS DIVERSE POPULATIONS. TO DEVELOP NOVEL INTERVENTIONS USING A MECHANISM-INFORMED, EXPERIMENTAL THERAPEUTICS APPROACH, AND, TO DEVELOP AND IMPLEMENT MEASUREMENT STRATEGIES TO FACILITATE MECHANISM-BASED INTERVENTION DEVELOPMENT AND TESTING. TO INVESTIGATE PERSONALIZED INTERVENTION STRATEGIES ACROSS DISEASE PROGRESSION AND DEVELOPMENT, AND, TO DEVELOP AND REFINE COMPUTATIONAL APPROACHES AND RESEARCH DESIGNS THAT CAN BE USED TO INFORM AND TEST PERSONALIZED INTERVENTIONS. TO DEVELOP AND TEST APPROACHES FOR ADAPTING, COMBINING, AND SEQUENCING INTERVENTIONS TO ACHIEVE THE GREATEST IMPACT ON THE LIVES AND FUNCTIONING OF PERSONS SEEKING CARE, TO CONDUCT EFFICIENT PRAGMATIC TRIALS THAT EMPLOY NEW TOOLS TO RAPIDLY IDENTIFY, ENGAGE, ASSESS, AND FOLLOW PARTICIPANTS IN THE CONTEXT OF ROUTINE CARE, AND, TO ENHANCE THE PRACTICAL RELEVANCE OF EFFECTIVENESS RESEARCH VIA DEPLOYMENT-FOCUSED, HYBRID, EFFECTIVENESS-IMPLEMENTATION STUDIES. TO EMPLOY ASSESSMENT PLATFORMS WITHIN HEALTHCARE SYSTEMS TO ACCURATELY ASSESS THE DISTRIBUTION AND DETERMINANTS OF MENTAL ILLNESSES AND TO INFORM STRATEGIES FOR IMPROVED SERVICES, TO OPTIMIZE REAL-WORLD DATA COLLECTION SYSTEMS TO IDENTIFY STRATEGIES FOR IMPROVING ACCESS, QUALITY, EFFECTIVENESS, AND CONTINUITY OF MENTAL HEALTH SERVICES, AND, TO COMPARE ALTERNATIVE FINANCING MODELS TO PROMOTE EFFECTIVE AND EFFICIENT CARE FOR INDIVIDUALS WITH SERIOUS EMOTIONAL DISTURBANCES AND SERIOUS MENTAL ILLNESSES. TO STRENGTHEN PARTNERSHIPS WITH KEY STAKEHOLDERS TO DEVELOP AND VALIDATE STRATEGIES FOR IMPLEMENTING, SUSTAINING, AND CONTINUOUSLY IMPROVE EVIDENCE-BASED PRACTICES, TO BUILD MODELS TO SCALE-UP EVIDENCE-BASED PRACTICES FOR USE IN PUBLIC AND PRIVATE PRIMARY CARE, SPECIALTY CARE AND OTHER SETTINGS, AND, TO DEVELOP DECISION-SUPPORT TOOLS AND TECHNOLOGIES THAT INCREASE THE EFFECTIVENESS AND CONTINUOUS IMPROVEMENT OF MENTAL HEALTH INTERVENTIONS IN PUBLIC AND PRIVATE PRIMARY CARE, SPECIALTY CARE, AND OTHER SETTINGS. TO ADAPT, VALIDATE, AND SCALE-UP PROGRAMS CURRENTLY IN USE THAT IMPROVE MENTAL HEALTH SERVICES FOR UNDERSERVED POPULATIONS, TO DEVELOP AND VALIDATE SERVICE DELIVERY MODELS THAT PROVIDE EVIDENCE-BASED CARE FOR INDIVIDUALS THROUGHOUT THE COURSE OF MENTAL ILLNESS, TO DEVELOP AND VALIDATE SYSTEMS-LEVEL STRATEGIES USING TECHNOLOGY AND OTHER APPROACHES, TO IDENTIFY, SUPPORT, AND MONITOR THE EFFECTIVENESS OF EVIDENCE-BASED CARE THROUGHOUT THE COURSE OF ILLNESS, AND, TO DEVELOP AND VALIDATE DECISION-MAKING MODELS THAT BRIDGE MENTAL HEALTH, MEDICAL, AND OTHER CARE SETTINGS TO INTEGRATE THE APPROPRIATE CARE FOR PEOPLE WITH SERIOUS MENTAL ILLNESSES AND COMORBID MEDICAL CONDITIONS.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Pennsylvania
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 06/30/24 to 06/30/26 and the total obligations have increased 2721% from $121,253 to $3,420,329.
Trustees Of The University Of Pennsylvania was awarded
Digital Platform Mental Health Support Healthcare Workers in COVID-19
Project Grant R01MH127686
worth $3,420,329
from the National Institute of Mental Health in July 2021 with work to be completed primarily in Pennsylvania United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.242 Mental Health Research Grants.
The Project Grant was awarded through grant opportunity Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional).
Status
(Ongoing)
Last Modified 7/3/25
Period of Performance
7/15/21
Start Date
6/30/26
End Date
Funding Split
$3.4M
Federal Obligation
$0.0
Non-Federal Obligation
$3.4M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01MH127686
Additional Detail
Award ID FAIN
R01MH127686
SAI Number
R01MH127686-785587323
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N700 NIH National Institute of Mental Health
Funding Office
75N700 NIH National Institute of Mental Health
Awardee UEI
GM1XX56LEP58
Awardee CAGE
7G665
Performance District
PA-90
Senators
Robert Casey
John Fetterman
John Fetterman
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute of Mental Health, National Institutes of Health, Health and Human Services (075-0892) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,462,203 | 66% |
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Health and Human Services (075-0886) | Health research and training | Grants, subsidies, and contributions (41.0) | $500,000 | 23% |
National Institute on Minority Health and Health Disparities, National Institutes of Health, Health and Human Services (075-0897) | Health research and training | Grants, subsidies, and contributions (41.0) | $240,000 | 11% |
Modified: 7/3/25